Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally

Executive Summary

FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year
Advertisement

Related Content

Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
Second Consecutive Year Of Growth In NME Approvals In The Cards For FDA
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
Last Gasp Or New Life? 2009's Novel Products Have Blockbuster Potential
FDA Clears Forest’s Savella, The First Fibromyalgia-Only Drug
CDER Closes Out 2008 With 24 Novel Approvals, But Few Are First In Class
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
FDA New Drug Review Performance May Miss Lowered Expectations – Jenkins
FDA Misses User Fee Goals As Resources Tighten For Application Reviews, SPAs
FDA First-Cycle Approval Rate Is Silver Lining In Cloud Of Low NME Count

Topics

Advertisement
UsernamePublicRestriction

Register

PS050589

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel